Mette Agger Net Worth

The estimated Net Worth of Mette Kirstine Agger is at least $7.37 Million dollars as of 16 March 2020. Ms. Agger owns over 187,500 units of scPharmaceuticals Inc stock worth over $7,321,209 and over the last 7 years she sold SCPH stock worth over $0. In addition, she makes $52,881 as Independent Director at scPharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Ms. Agger SCPH stock SEC Form 4 insiders trading

Mette has made over 2 trades of the scPharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she bought 187,500 units of SCPH stock worth $3,000,000 on 16 March 2020.

The largest trade she's ever made was buying 375,000 units of scPharmaceuticals Inc stock on 9 May 2019 worth over $3,750,000. On average, Mette trades about 62,500 units every 35 days since 2017. As of 16 March 2020 she still owns at least 1,432,722 units of scPharmaceuticals Inc stock.

You can see the complete history of Ms. Agger stock trades at the bottom of the page.

Mette Agger biography

Mette Kirstine Agger serves as Independent Director of the Company. Since 2009, Ms. Agger has served as a managing partner of Lundbeckfonden Ventures, a life science venture fund. Prior to that, Ms. Agger co-founded 7TM Pharma A/S, a biotech company engaged in therapeutic drug discovery and development, in 2000, and served as its chief executive officer from founding to 2009. Prior to founding 7TM Pharma, Ms. Agger was part of the management team of NeuroSearch A/S, a former drug research and development company. Ms. Agger serves on numerous boards of both in private and public companies, including Klifo, a pharmaceutical consulting company, Cydan Development, an orphan drug startup accelerator, Imara, a sickle cell disease focused drug company, Psioxus, an immuno-oncolytic virus company, Tiburio Therapeutics, treatment of non-functioning pituitary adenoma, Trevi Therapeutics, a late-stage clinical development company, and Veloxis, an emerging specialty pharmaceutical company. Ms. Agger graduated with an M.Sc. in Biology from the University of Copenhagen and has an M.B.A. from Henley Business School University of Reading.

What is the salary of Mette Agger?

As the Independent Director of scPharmaceuticals Inc, the total compensation of Mette Agger at scPharmaceuticals Inc is $52,881. There are 6 executives at scPharmaceuticals Inc getting paid more, with John Tucker having the highest compensation of $1,238,320.

How old is Mette Agger?

Mette Agger is 55, she's been the Independent Director of scPharmaceuticals Inc since 2014. There are 8 older and 3 younger executives at scPharmaceuticals Inc. The oldest executive at scPharmaceuticals Inc is Leonard Schaeffer, 74, who is the Independent Director.

What's Mette Agger's mailing address?

Mette's mailing address filed with the SEC is C/O SCPHARMACEUTICALS INC, 25 BURLINGTON MALL ROAD, SUITE 203, BURLINGTON, MA, 01803.

Insiders trading at scPharmaceuticals Inc

Over the last 7 years, insiders at scPharmaceuticals Inc have traded over $5,999,254 worth of scPharmaceuticals Inc stock and bought 6,409,552 units worth $61,370,807 . The most active insiders traders include Capital Management, L.P.Ra ..., Jonathan Silverstein, and Advisors Llc Orbi Med Capit.... On average, scPharmaceuticals Inc executives and independent directors trade stock every 112 days with the average trade being worth of $1,808,281. The most recent stock trade was executed by Leonard D Schaeffer on 26 August 2024, trading 11,347 units of SCPH stock currently worth $29,275.

What does scPharmaceuticals Inc do?

scpharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that, through our proprietary platform, are designed to enable the subcutaneous administration of therapies previously limited to intravenous (iv) delivery—with the goal of transforming infused therapies, advancing patient care, and reducing healthcare costs.

Complete history of Ms. Agger stock trades at scPharmaceuticals Inc, Imara Inc, and Trevi Therapeutics

scPharmaceuticals Inc executives and stock owners

scPharmaceuticals Inc executives and other stock owners filed with the SEC include:

• John Tucker,
  President, Chief Executive Officer, Principal Executive Officer, Principal Financial Officer and Director
• John H. Tucker,
  Pres, CEO, Principal Exec. Officer, Principal Financial Officer & Director
• Rachael Nokes,
  Senior Vice President - Finance, Principal Accounting Officer
• Rachael Nokes,
  Sr. VP of Fin. & Principal Accounting Officer
• Jack Khattar,
  Independent Chairman of the Board
• Frederick Hudson,
  Independent Director
• Mette Agger,
  Independent Director
• Klaus Veitinger,
  Independent Director
• Minnie Baylor-Henry,
  Independent Director
• Leonard Schaeffer,
  Independent Director
• Mason Freeman,
  Independent Director
• Katherine Taudvin,
  Director, Corporate Development, Investor Relations
• Sara Bonstein,
  Independent Director
• Michael D. Hassman,
  Sr. VP of Technical Operations
• Dr. John Mohr Pharm.D.,
  Sr. VP of Clinical Devel. & Medical Affairs
• Capital Management, Llcra C...,
  
• Invest A/S Lundbeckfond,
  10% owner
• Advisors Llc Orbi Med Capit...,
  
• Dorothy Coleman,
  Director
• Jonathan Silverstein,
  Director
• Pharmaceutical Industries L...,
  
• Troy A. Ignelzi,
  Chief Financial Officer
• Abraham Ceesay,
  Chief Operating Officer
• Kush Parmar,
  Director
• Andrew J. Schwab,
  10% owner
• Advisors Llc Orbi Med Capit...,
  
• Capital Management, L.P.Ra ...,
  
• Partners Iv, Llc5 Am Co Inv...,
  
• William Tober Abraham,